Cannabis Campaigners' Guide News Database result:


After you have finished reading this article you can click here to go back.

UK: GW says cannabis may treat arthritis

Reuters

Wednesday 09 Jun 2004

---

LONDON (Reuters) - A pioneering cannabis-based medicine, initially
developed to help multiple sclerosis sufferers, can also reduce arthritis
pain, the company behind the product says.

GW Pharmaceuticals, which is awaiting approval from UK and Canadian
regulators to use its Sativex spray to treat MS and severe neuropathic
pain, said on Wednesday mid-stage Phase II clinical tests showed it could
benefit rheumatoid arthritis patients.

"These results are particularly exciting because this is the first ever
controlled clinical trial of a cannabis-based medicine in the treatment of
arthritis," said Philip Robson, director of GW's Cannabinoid Research
Institute.

"This exploratory trial provides further strong support to our belief that
cannabis-based medicines may offer therapeutic potential across a range of
medical conditions."

Sativex is partnered with Germany's Bayer AG.

GW, which grows more than 40,000 marijuana plants a year at a secret
location in the English countryside, said some 400,000 adults in the UK
have rheumatoid arthritis.

 

 

 

After you have finished reading this article you can click here to go back. 




This page was created by the Cannabis Campaigners' Guide.

Feel free to link to this page!